ClinVar Miner

Submissions for variant NM_002485.4(NBN):c.1354A>C (p.Thr452Pro) (rs141137543)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000735122 SCV000885816 uncertain significance not provided 2017-11-24 criteria provided, single submitter clinical testing
Ambry Genetics RCV000131458 SCV000186442 uncertain significance Hereditary cancer-predisposing syndrome 2017-05-08 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence
Color RCV000131458 SCV000910678 likely benign Hereditary cancer-predisposing syndrome 2015-11-17 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000735122 SCV000863322 uncertain significance not provided 2018-09-18 criteria provided, single submitter clinical testing
GeneDx RCV000212747 SCV000211450 likely benign not specified 2017-09-12 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Genetic Services Laboratory, University of Chicago RCV000212747 SCV000595915 uncertain significance not specified 2017-02-07 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000212747 SCV000917862 uncertain significance not specified 2018-08-01 criteria provided, single submitter clinical testing Variant summary: NBN c.1354A>C (p.Thr452Pro) results in a non-conservative amino acid change located outside of any known functional domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0. 0.00026 in 276950 control chromosomes, predominantly observed within the African subpopulation at a frequency of 0.0025 in the gnomAD database. The observed variant frequency within African control individuals is approximately 20 fold of the estimated maximal expected allele frequency for a pathogenic variant in NBN causing Hereditary Breast and Ovarian Cancer (HBOC) phenotype (0.00013), suggesting that the variant is a benign polymorphism found primarily in populations of African origin. Moreover, the variant was also identified in 22/2559 African American (with a frequency of 0.0086) and 1/7325 of European American women who are cancer free at age over 70 in the FLOSSIES database. c.1354A>C has been reported in the literature in individuals affected with Breast cancer, Endometrial cancer and Lynch syndrome (Tung 2016, Ring 2016, and Yurgelun 2015). In one of these publications, a co-occurrence with a pathogenic variant has been reported (MLH1 c.677G>A (p.Arg226Gln)), providing supporting evidence for a benign role in this patient with Lynch Syndrome (Yurgelun 2015), however, the association of c.1354A>C with HBOC remains uncertain. A case control study found the variant to occur mainly in the African American cohort, both in breast cancer cases and controls, however sample sizes in each racial/ethnic group were relatively small to establish a clear relationship between the variant and breast cancer risk (Haiman 2013). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (Likely benign (2x) and VUS (2x)). Based on the evidence outlined above, the variant was classified as VUS-possibly benign.
Invitae RCV000199946 SCV000253386 likely benign Microcephaly, normal intelligence and immunodeficiency 2017-12-10 criteria provided, single submitter clinical testing
Mendelics RCV000199946 SCV000838303 uncertain significance Microcephaly, normal intelligence and immunodeficiency 2018-07-02 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.